Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 6/20 | 0.45 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6576992 | 0.85 | SRC (0.56) | SRCHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL6576078 | 0.80 | CDK1 (0.69) | SRCCDK1CDK2PDGFRACCNE1 | |
| SCHEMBL6576281 | 0.80 | CDK1 (0.69) | SRCCDK1CDK2PDGFRACCNE1 | |
| SCHEMBL6574923 | 0.80 | CDK1 (0.69) | SRCCDK1CDK2PDGFRACCNE1 | |
| SCHEMBL6576297 | 0.80 | CDK1 (0.69) | SRCCDK1CDK2PDGFRACCNE1 | |
| SCHEMBL183315 | 0.80 | SRC (0.61) | SRCHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL6574795 | 0.78 | CDK1 (0.68) | SRCCDK1CDK2PDGFRACCNE1 | |
| SCHEMBL6574786 | 0.78 | CDK1 (0.68) | SRCCDK1CDK2PDGFRACCNE1 | |
| Carbamic Acid SCHEMBL6576937 | 0.78 | CDK1 (0.54) | SRCCDK1CDK2PDGFRACCNE1 | |
| SCHEMBL5840144 | 0.78 | CDK1 (0.65) | SRCHDAC1HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1183133-C | 2-amino-6-anilino-purines and their use as medicaments | ��˹��ŵ�� | 2005-01-05 | — | — | CN | disclosed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| CN-1340054-A | 2-amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | SRC 54/4885HDAC1 4650/4885HDAC2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.